SUN PHARMA Q4 : CON NET PROFIT DOWN 19 % AT 2153 CR (YOY), DOWN 26.1 % (QOQ) REVENUE UP 8.1 % AT 12958 CR (YOY) , DOWN 5.2 % (QOQ) EBITDA UP 22.4 % AT 3716 CR (YOY), DOWN 7.3 %(QOQ) MARGINS AT 28.67 % V 25.32 % (YOY), 29.31 % (QOQ)